Lameness Repair Company

PetVivo’s CTO Receives Award

Press Release PetVivo’s CTO Receives Award

(All Press Releases Will Be Available for Viewing on Facebook or the Web at www.petvivo.com)

 

Created:

Thursday, July 6, 2017

For Immediate Release:

 

PetVivo’s Dr. Masters Receives Award from Society for Biomaterials

 

PetVivo Holdings, Inc. (www.petvivo.com) an emerging biomedical device company focused on commercialization of innovative medical devices and therapeutics continues to receive recognition for its novel orthopedic devices. PetVivo’s Chief Technical Officer David B. Masters, Ph.D. has received the Star Abstract Award from the Orthopedics Biomaterials Special Interest Group, Society for Biomaterials. The award, which acknowledges significant advances in the field, recognizes abstracts that have an average abstract review score greater than or equal to 4.0 on a 1-5 scale.

Dr. Masters’ oral presentation of the award abstract is titled “Particles for Osteoarthritis Treatment: Injected Wet Particulate of Collagen-Elastin-Glycosaminoglycan Matrix into Synovial Fluid Mechanically Cushion Joint with Long Duration”.

“It is an honor to be recognized by scientists in your field of study,” noted Dr. David Masters. “Leading biomaterial experts are increasingly recognizing the importance of incorporating natural biochemical components into their studied polymer biomaterials to help promote natural regeneration of tissue. We have been fortunate to be early adopters in utilizing collagen and its elastin-carbohydrate tissue counterparts to formulate a strong natural biomaterial matrix, allowing our company to carve out significant intellectual property around protein based device configurations that naturally help the body heal and protect itself.”

Dr. Masters also concludes: “Our MasterGel Hydrophilic Biomaterial (MHB) particles provide safe cushioning and lubricity to the joint, as well as a scaffolding that can help natural healing processes rebuild functional tissue. In this way, MHB particles alleviate the pain associated with missing and damaged cartilage to provide a protective environment in much the same way native cartilage protects the joint. Our MHB scaffolding imparts a chemical-structural feedback for natural cell-mediated responses, which allows implanted grafts and devices to integrate and/or regenerate endogenous tissues.

“For example, our biomaterial has been used in a number of tissue applications, including spinal disks, tissue glue, cosmetic dermal filler for skin wrinkle repair (clinicaltrials.gov NCT00414544), urinary sphincter muscle regeneration, blood vessel grafts and more, including over $5 million in National Institutes of Health funding. Indeed, we show that the current treatment for canine osteoarthritis, which relies on constant NSAID medication, can be eliminated for about a year following a single injection of MHB particles.” Dr. Masters’ complete abstract can be found here.

The MHB Particles are used in the production of PetVivo’s lead product, Kush Canine for the treatment of canine osteoarthritis. Kush Canine is scheduled for commercial launch later this year, followed shortly thereafter by Kush Equine for the treatment of lameness in horses. The particles used to make the Kush devices are part of a large pipeline of patented animal and human therapeutics developed and manufactured by Gel-Del® Technologies.

You can learn more about Kush Canine and PetVivo by visiting the company’s website at www.petvivo.com

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

PetVivo Holdings, Inc. routinely posts periodic reports and press releases that includes important information on our corporate website and/or Facebook page. Therefore, for more information please see us on Facebook and visit at our website at www.petvivo.com.

Forward-Looking Statements:

 

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

PetVivo’s Kush Canine is Helping Rescue Dogs To Thrive

For Immediate Release:

PetVivo’s Kush Canine is Helping Rescue Dogs To Thrive

 

MINNEAPOLIS, MN October 12, 2016 PetVivo Holdings, Inc. (OTCPINK:PETV) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for pets is seeing long-term success by allowing rescue dogs suffering from osteoarthritis and joint pain to thrive.

Kush Canine is helping rescue agency dogs who under foster family care to improve their quality of life – immediately and long-term. A foster parent commented, “Immediately after Kush Canine treatment our dog walked up and down the outside concrete stairs, something he resisted prior to the treatment with Kush.”

Five days following Kush Canine treatment a rescue dog caretaker noted, “He is much changed.  Primarily, he seems to have more confidence, and is rapidly becoming the alpha dog in the house.”

In a follow-up nine days after a Kush Canine injection the foster parent of a twelve-year-old Labrador Retriever commented, “Raider continues to rejuvenate daily. It is no exaggeration to say this is a different dog. He is so much happier, bossier and playful. Rather than dragging himself behind Madden, they are now playful buddies.

Because the protein-based particles in Kush Canine are not enzymatically degraded they remain in the joint space long-term and continue to act as artificial cartilage by providing cushioning that improves joint function and often eliminates pain.  Three-months following Kush treatment Raider’s foster parent noted, “Our friend Raider continues to thrive. It is not just movement. It is personality.”

“We are very pleased to help improve the quality of life of these suffering dogs,” noted PetVivo’s Chief Technical Officer, Dr. David B. Masters, “We have seen similar results well beyond twelve months in both dogs and horses. We look forward to helping others suffering from debilitating and painful effects of osteoarthritis and other afflictions that degrade joint function.”

PetVivo’s lead product, Kush Canine, a Veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is currently available for sale in limited quantities to key opinion leaders, with a targeted launch slated for later this year.

You can learn more about Kush Canine and PetVivo by visiting the company’s website at www.petvivo.com

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

PetVivo’s Kush Continues to Demonstrate Effectiveness

For Immediate Release:

PetVivo’s Kush Continues to Demonstrate Effectiveness

MINNEAPOLIS, MN September 23, 2016 PetVivo Holdings, Inc. (OTCPINK:PETV) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for pets continues to see positive results from Kush treatments to both dogs and horses.

A particularly interesting case is a seven-year-old thoroughbred named Sarge Hudson. Sarge suffered from bone deterioration and cartilage loss in his left ankle (fetlock) joint and it was assumed he would never race again. The horse was given away to a new owner Dustin Williams at no cost. Dustin had both of Sarge Hudson’s fetlocks treated with PetVivo’s Kush particles. The Kush treatments allowed Sarge to return to racing. On August 19 at the Columbus Park track in Columbus, Nebraska Sarge Hudson ran to a first place finish in Race number six. Eight days flowing his win, Sarge went on to a third place finish.

“I am very impressed that the Kush Particles allowed Sarge to return to the track,” noted Dustin William, “It is even more impressive that Sarge returned to the track with a win!”

“We are very optimistic about our Kush product to protect the joint from further damage caused by the lost cartilage and to alleviate the associated pain”, notes Dr. David B. Masters, PetVivo’s Chief Technology Officer. “By replacing the cushion lost by the joint’s damaged cartilage, Kush particles injected into the synovial fluid augment the cartilage effects in the articulating joint space, thus allowing the horse to run without the limiting joint pain.”

PetVivo’s lead product, Kush Canine, a Veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is currently available for sale in limited quantities to key opinion leaders, with a targeted launch slated for later this year.

You can learn more about Kush Canine and PetVivo by visiting the company’s website at www.petvivo.com

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

PetVivo Continues IP Portfolio Expansion

News Release

PetVivo Continues IP Portfolio Expansion

MINNEAPOLIS, MN August 22, 2016 PetVivo Holdings, Inc. (OTCPINK:PETV) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics is pleased to announce that the European Patent Office has granted a patent securing Gel-Del’s intellectual property related to orthopedic fracture fixation devices. This patent represents significant market opportunities in both the companion animal and human clinical markets. With the issuance of this patent the company’s global patent portfolio has grown to twenty patents, including eight in the US, with an additional seventeen global patent applications pending.

This patent, titled “Biomatrix Structural Containment and Fixation Systems”, secures intellectual property with medical devices that include orthopedic fracture fixation systems that enable bones to heal across separated defects. This osteoconductive regeneration system uses both biomatrix particles to induce and direct bone growth and a biomatrix sleeve to contain the particles to the defect zone. The sleeve also provides a bridge to connect the vascularized periosteum across the defect, and importantly isolates the defect from soft tissue intrusion and interference to allow the particles to bridge the nonunion. This technology offers a new and simplified treatment method for fractures that are exceptionally difficult to treat.

 

This technology may also be utilized to repair fractures or damage to other parts of the body such as tendons and nerves (e.g. spinal cord and optical nerve). These therapies improve upon current therapies by using both a containment sleeve to isolate bone, tendon or nerve healing from soft tissue and by adding therapeutic bone, tendon or nerve mending particles to act as healing scaffolds, both of which can provide local drug delivery and local cell integration to the site of healing. The United States Patent Office has already granted a corresponding patent relating to these devices.

 

“We are very pleased with the continued expansion of our intellectual property portfolio around the globe,” noted PetVivo’s Chief Technical Officer, Dr. David B. Masters. “The European Patent Office has comprehensively granted the same matter as the US Patent and Trademark Office to recognize the uniqueness and broad inventiveness of our natural protein biomaterials and their benefits to create better tissue safe-medical implants and drug delivery device platforms.”

 

The company diligently protects their proprietary technologies, including the composition of raw elements used to produce its formulations, as well as the fabricated biomaterials and their application in end products and devices. To maximize the strength and value of the company’s intellectual property the claims generally cover the commercial devices/therapeutics, the manufacturing methods and the methods of use of its devices/therapeutics.

 

PetVivo’s lead product, Kush Canine, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is available for sale in limited quantities to key opinion leaders, with a targeted launch slated for later this year.

You can learn more about Kush Canine and PetVivo by visiting the companies website at www.petvivo.com

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

Forward-Looking Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

Dr. Michael Sterns Joins PetVivo Advisory Board

Dr. Michael Sterns Joins PetVivo Advisory Board

MINNEAPOLIS, MN July 11, 2016 PetVivo Holdings, Inc. (OTCPINK:PETV) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for pets is very pleased to announce that Michael Sterns, DVM has joined the PetVivo Veterinary Advisory Board. Dr. Sterns brings PetVivo more than thirty years of clinical and commercial experience in the veterinary field.

Dr. Sterns earned his BS in Biological Sciences (magna cum laude, Phi Beta Kappa) from the University of Southern California in 1980. After graduating from the UC Davis School of Veterinary Medicine in 1984, he began his career as an Equine Veterinarian. Dr. Sterns earned his MBA from the Haas School of Business at UC Berkeley in 1990, and spent the next twenty-three years raising greater than $200 million in private and public equity, negotiating licensing deals, and building start-ups in human and veterinary therapeutics, medical devices and research tools.

Dr. Sterns returned to clinical practice in 2012, and is now a mobile Veterinaruan with VetPronto, a san Francisco Bay Area start up, and also practices part time general small animal medicine and surgery at Alta View Animal Hospital in Mountain View, California.

“We are extremely pleased to have Dr. Sterns join our Advisory Board,” commented PetVivo’s CEO John Lai, “Michael brings a unique blend of large and small animal practice experience in addition to extensive industry experience to help guide PetVivo’s growth.”

PetVivo’s lead product, Kush Canine, a Veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is available for sale in limited quantities to key opinion leaders, with a targeted launch slated for later this year.

You can learn more about Kush Canine and PetVivo by visiting the companies website at www.petvivo.com

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

PetVivo’s Corporate Presentation can be found here:

http://petvivo.com/wp-content/uploads/2016/04/PetVivo-Corp-Deck-04-01-16.pdf

Forward-Looking Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

Veterinary Experts Join PetVivo Advisory Board

Veterinary Experts Join PetVivo Advisory Board

MINNEAPOLIS, MN May 26, 2016 PetVivo Holdings, Inc. (OTCPINK:PETV) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for pets is very pleased to announce that John Wagoner and Brian Barnett, DVM have joined the PetVivo Veterinary Advisory Board. Mr. Wagoner and Dr. Barnett each bring the company more that twenty years of experience in the veterinary field.

Dr. Barnett is the owner and Chief of Staff at Randolph Animal Hospital as well as the newly opened Biscoe Pet Hospital, in the Greensboro/Winston-Salem, North Carolina Area. In addition, Dr. Barnett is a member of the Veterinary Management Group 21 (VMG-21) and serves as staff veterinarian for High Point, NC based Trone Marketing. Trone has a strong presence in the veterinary market, including marketing of the Greenies brand.

Dr. Barnett earned his Bachelors of Science in Zoology from Auburn University and Doctor of Veterinary Medicine from Auburn University’s College of Veterinary Medicine. In addition to his science and veterinary degrees, Dr. Barnett holds an MBA from Wake Forest’s Babcock School of Management.

John Wagoner brings extensive veterinary distribution management expertise to PetVivo. John is a co-founder of Boomerang Vet a data-based client communications service for Veterinary Hospitals located in Columbus, Ohio. In 2003, John founded, managed and grew CSC South Veterinary Supplies into the second largest veterinary distribution company in the Southeast region. In 2008, he sold CSC South Veterinary Supplies to Patterson Companies, Inc.

PetVivo’s CEO John Lai commented, “We are very pleased to have Mr. Wagoner & Dr. Barnett join our Veterinary Advisory Board. They each bring extensive veterinary industry experiences and unique skill sets to help guide us in commercializing our companion animal products.”

PetVivo’s lead product, Kush Canine, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is available for sale in limited quantities to key opinion leaders, with a targeted launch slated for later this year.

Dr. Barnett, who has had the opportunity to treat canine patients suffering from osteoarthritis with the Kush device at Randolph Animal Hospital, commented, “While my experience and observations of the Kush product are limited in duration, I believe this product has demonstrated effectiveness in treating canine OA joints. This product shows much potential in serving the very large arthritic canine population and is a product that can help grow my practice.”

You can learn more about Kush Canine and PetVivo by visiting the companies website at www.petvivo.com

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

PetVivo’s strategy is to commercialize proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.

The Company will also be seeking licensing partners to commercialize its portfolio of proprietary human clinical therapeutics in large market sectors, including: cardiovascular, orthopedic, urology and aesthetics.

PetVivo’s Corporate Presentation can be found here:

http://petvivo.com/wp-content/uploads/2016/04/PetVivo-Corp-Deck-04-01-16.pdf

Forward-Looking Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

PetVivo Expands IP Assets With EU Drug Delivery Patent Grant

News Release

 

 

PetVivo Expands IP Assets With EU Drug Delivery Patent Grant

MINNEAPOLIS, MN October 26, 2015 PetVivo Holdings, Inc. (OTCPINK:PETV) an emerging biomedical device company focused on the commercialization of innovative medical devices for pets or pet therapeutics is pleased to announce the issuance of European Patent 1691746. With this recent issuance by the European Patent Office, PetVivo’s intellectual property portfolio has grown to twenty patents, eight of which are United States Patents. The company has an additional seventeen patent applications pending in the United States and strategic foreign countries.

 

This recently issued European Patent “Mucoadhesive Drug Delivery Devices and Methods of Making and Using Thereof,” secures twenty-six patent claims, including three independent claims related to the localized and systemic delivery of pharmacologically active agents through all types of mucosal tissues for the treatment of diseases, infections, wounds, inflammation/pain and other afflictions. Mucosal drug delivery is generally noninvasive and the attachment of the mucosal drug delivery device protects the pharmacologically active agents from elimination at the drug absorption site, thereby increasing drug absorption and bioavailability.

 

“We now possess the intellectual property to protect our proprietary mucosal delivery products and their veterinary and human treatment applications,” commented PetVivo’s CTO, Dr. David B. Masters, “This degradable mucosal attachment technology provides greater residency time to improve therapeutic effectiveness for a broad range of products, including delivery of nutraceuticals, vitamins, oral care agents, and a wide range of pharmaceuticals. We are pleased to have patent protection for our transmucosal delivery system that will initially target the dental hygiene, pain and incontinence markets in the veterinary space.”

 

This mucoadhesive drug delivery patent protects a broad range of human and animal therapeutics representing many significant market opportunities. One of the technologies covered in this patent is the mucosal pharmaceutical delivery system, OraPatch™, which is a slowly degradable protein wafer-disc that strongly attaches to and assimilates with the oral cavities mucosal membrane. OraPatch provides a nearly undetectable and secure mucosal attachment for the controlled release period so its contents can circulate within the mouth longer as it degrades away to dissolved material. In addition, OraPatch can be fabricated for transmucosal delivery, eliminating gastrointestinal tract issues that can be caused by traditional oral pharmaceutical delivery, enhancing bioavailability and reducing the amount of pharmacologically active agent needed.

The United States Patent and Trademark Office has previously issued a corresponding patent number 8,529,939 titled “Mucoadhesive Drug Delivery Devices and Methods of Making and Using Thereof”. In addition, both the Canadian and Australian Patent Offices have also allowed a corresponding patent.

 

“We are pleased to see the ongoing expansion of the intellectual property related to our medical device and drug delivery device platforms. This expansion highlights the novelty of our many protein based materials and devices,” commented PetVivo CEO John Lai, “We continue to show that our protein particles improve the quality of life for dogs and horses suffering from osteoarthritis. We are seeing success beyond eighteen months after a single treatment of the Kush particles.”

 

To treat lameness a licensed veterinarian injects the Kush particles into the affected joints. Kush’s soft, resilient particles work by providing a protective cushion to the joint where its natural cartilage is missing or damaged. These particles are formulated to provide the mechanical support required to absorb the forces found in an articulating joint.

 

PetVivo’s research estimates that osteoarthritis and lameness currently impacts twenty million dogs and one million horses in the United States and Europe. The Kush devices are part of a portfolio of more than seventeen therapeutic candidates in various stages of development for both veterinary and human clinical applications.

 

The company diligently protects its proprietary technologies, including the composition of raw elements used to produce its formulations, the fabricated biomaterials and their application in end products and devices. To maximize the strength and value of PetVivo’s intellectual property the claims generally cover the commercial devices/therapeutics, the manufacturing methods and the methods of use of the company’s proprietary technology.

 

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

 

PetVivo’s strategy is to acquire or in-license proprietary products from human medical device companies specifically for the companion animal market. The company’s product pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.

 

For more information, visit: www.PetVivo.com

 

Forward-Looking Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

PetVivo Enhances Its Proprietary Position with Key US Patent Grant

News Release

 

 

PetVivo Enhances Its Proprietary Position with Key US Patent Grant

 

MINNEAPOLIS, MN May 20th, 2015 PetVivo Holdings, Inc. (OTCPINK:PETV) an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and therapeutics for pets is pleased to announce that the United States Patent and Trademark Office (USPTO) has allowed an important patent related to wound healing treatments. The open-ended nature of the issued claims in this patent, entitled “Protein Biomaterials and Biocoacervates and Methods of Making and Using Thereof,” provides tremendous proprietary protection for a broad range of wound healing treatments, including the treatment of osteoarthritis.

 

“Our biomaterial technology and the claims issued in our patents provide us extremely comprehensive coverage. This divisional patent extends our patent claims to include the use of our particles for wound healing applications, as well as the use of this proprietary material in any shape or coating to greatly extend the scope of our device and drug delivery applications,” noted PetVivo Chief Technology Officer, Dr. David Masters. “In addition, the claims covering wound healing devices disclosed in this newly allowed patent application provides proprietary protection for our Kush™ Canine particles.”

 

With this recent wound healing patent allowance by the USPTO, PetVivo’s intellectual property portfolio has grown to twenty allowed patents, eight of which are United States patents. PetVivo has an additional sixteen patent applications pending in the US and in strategic foreign countries.

 

“It is exciting to see the ongoing expansion of our intellectual property. This expansion highlights the novelty of our biomaterials, devices and treatments including our lead product Kush Canine,” commented PetVivo CEO John Lai. “We look forward to improving the quality of life for osteoarthritic dogs and their owners with the launch of Kush Canine slated for later this year.”

 

PetVivo diligently protects its proprietary technologies, including the composition of raw elements used to produce its formulations, the fabricated biomaterials and their application in end products and devices. To maximize the strength and value of its intellectual property the claims generally cover the commercial devices/therapeutics, the manufacturing methods and the methods of use of PetVivo’s proprietary technology.

 

PetVivo recently completed a merger with Gel-Del Technologies. As a wholly-owned subsidiary of PetVivo Holdings, Gel-Del Technologies will continue its operations as the manufacturing and product development division of PetVivo Holdings.

 

About PetVivo Holdings, Inc.

PetVivo Holdings Inc. (OTCPINK: PETV) is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets and pet therapeutics. PetVivo is leveraging investments made in the human medical device industry to commercialize therapeutics for pets in a capital and time efficient way. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

 

PetVivo’s strategy is to acquire or in-license proprietary products from human medical device companies specifically for the companion animal market. The company’s pipeline includes seventeen animal and human therapeutics. A portfolio of twenty patents protects the company’s products, production processes and biomaterials. PetVivo’s lead product, a veterinarian-administered joint injection for the treatment of osteoarthritis in dogs, is scheduled for commercial launch later this year.

 

For more information, visit: www.PetVivo.com

 

Forward-Looking Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

PetVivo’s Kush Devices Gain Further IP Protection With Patent Allowance

PetVivo’s Kush Devices Gain Further IP Protection With Patent Allowance

 

MINNEAPOLIS, MN March 25th, 2015 PetVivo Holdings, Inc. (OTCPINK:PETV) an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets or pet therapeutics is pleased to announce an additional patent allowance for its merging partner Gel-Del Technologies, Inc. This Canadian Patent allowance secures intellectual property related to PetVivo’s Kush device for the treatment of osteoarthritis and other particle devices. PetVivo Holdings and Gel-Del Technologies previously announced that they entered into a definitive stock exchange agreement that is scheduled to close by March 31, 2015.

 

Titled “Biocompatible Protein Particles, Particle Devices and Methods Thereof” the allowed patent secures additional claims related to the biocompatible protein particulate material used to produce Kush and other particulate devices as well as their therapeutic applications. Upon dissuance this patent will increase the Gel-Del global portfolio to nineteen patents, including seven US patents, with an additional seventeen pending in the US and strategic foreign countries.

 

“It is exciting to see the ongoing expansion of the intellectual property related to our devices. This expansion highlights the novelty of our treatments including our lead product Kush Canine,” commented PetVivo CEO John Lai, “We look forward to improving the quality of life for osteoarthritic dogs and their owners with the launch of Kush Canine slated for Q3 of this year.”

 

To treat lameness the Kush protein matrix particles are injected by a licensed veterinarian into the joint’s synovial fluid to provide a protective cushion where the joint’s natural cushioning cartilage is missing. A simple explanation is that the Kush device provides soft, resilient particles to the joint to replenish the slippery cushioning characteristics of the missing or damaged cartilage. These particles provide the mechanical support required to absorb the forces found in an articulating joint.

 

“Our particle technology continues to gain broader patent protection for our many device applications including our arthritic joint treatment, Kush.” commented Gel-Del’s CEO, Dr. David B. Masters “We believe our Kush particles can provide the functionality of cartilage to alleviate pain, halt the progression of further damage, and allow native reparative healing to occur in afflicted joints.”

 

PetVivo’s market research indicates that osteoarthritis and lameness currently impacts twenty million dogs and one million horses in the United States and Europe. The Kush devices are part of a portfolio of more than seventeen therapeutic candidates in various stages for development for both veterinary and human clinical applications.

 

About Gel-Del Technologies, Inc.

Gel-Del Technologies (www.gel-del.com) is a biomaterial and medical device manufacturing company based in St. Paul, Minnesota. The company successfully completed a pivotal clinical trial using their novel thermoplastic biomaterial as an injected dermal filler for human facial contour applications (clinicaltrials.gov NCT00414544).

 

Gel-Del’s core competencies include the development and manufacturing of medical devices containing its proprietary biomaterials with or without pharmaceuticals. Using its patented thermoplastic and/or compression manufacturing technologies, purified proteins and carbohydrates are accurately self-assembled and fabricated into cell supporting and tissue compatible biomaterial scaffolds. These “made from scratch” biological scaffolds have the hydrophilic biomimetic structure of the body’s non-cellular tissue allowing in vivo biochemical interaction, cellular integration, neovascularization, tissue repair, tissue absorption and regeneration as a temporary or permanent implant. This biomaterial platform has an interlocking proteinaceous structure with inherit molecular forces to contain added components and/or allow their elution for drug delivery at prescribed durations to any body tissue (e.g., transmucosal, injected or implant depots for minutes to months duration).

 

These non-soluble biomaterials are produced using a patented and reproducible-scalable process that is FDA-validated for human clinical trial production. The inherent properties of these biomaterials allow thermoplastic, compression molding or liquid coating techniques to manufacture implantable devices of all shapes and sizes, including particles for injection and as drug delivery devices at any pharmaceutical dose.

 

About PetVivo, Inc:

PetVivo, Inc. is a wholly owned subsidiary of PetVivo Holdings, Inc. (OTCPINK:PETV) based in Minneapolis, Minnesota. PetVivo is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and other therapeutics for pets.

 

PetVivo believes that it can leverage the investments in the human biomaterials and medical device industries to commercialize therapeutics to pets in a capital and time efficient way. PetVivo’s strategy is to in-license proprietary products from human medical device companies specifically for use in pets. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

 

Forward-Looking Statements:

The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

PetVivo’s Merger Partner Strengthens Canadian IP Portfolio with Stent Patent Allowance

PetVivo’s Merger Partner Strengthens Canadian IP Portfolio with Stent Patent Allowance

MINNEAPOLIS, MN March 9th, 2015 PetVivo Holdings, Inc. (OTCPINK:PETV) an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and therapeutics for pets is pleased to announce that the patent portfolio of its merging partner Gel-Del Technologies, Inc. has grown to eighteen allowed patents, with an additional eighteen patent applications pending in the US and strategic foreign countries. PetVivo Holdings and Gel-Del Technologies previously announced that they entered into a definitive stock exchange agreement that is scheduled to close by March 31, 2015.

PetVivo CEO John Lai noted, “While the pending launch of our Kush™ device for the treatment of osteoarthritis in companion animals remains our first priority we are very pleased with the continued expansion of Gel-Del’s intellectual property portfolio. We see many opportunities for introducing our tubular conduit devices and coated stents to provide first-mover advantages in both the veterinary and clinical sectors.”

Titled “Encapsulated or Coated Stent Systems”, this patent allowance by the Canadian Intellectual Property Office has a corresponding US Patent 8,465,537. These patents help secure the intellectual property related to stents that are coated or encapsulated with Gel-Del’s proprietary non-clotting regenerative biomaterials. The self-assembled protein-based scaffolds have inherent drug delivery capabilities that allow coated stents and stent grafts to elute active compounds for many weeks to months. Gel-Del’s stent and lumen devices have a variety of veterinary and human applications.

Gel-Del’s product development efforts for vascular grafts, stents, catheters and drug delivery devices have been supported by $6.6 million in competitive National Institute of Health grant funding. The vast majority of the funding was received from the National Heart, Lung and Blood Institute under the project title “Arterial-Mimetic Grafts Molded From Purified Proteins”. This funding allowed for over five years of extensive testing of Gel-Del’s vascular devices, including both swine and sheep, and demonstrated the efficacy of these devices for smaller diameters required for companion animal applications. In addition, these NIH studies have advanced the pre-clinical studies required for human use, which includes coronary artery bypass grafts to prevent heart attacks.

“We are pleased to have another stent patent allowance for our medical device technology,” commented Gel-Del’s CEO, Dr. David B. Masters. “There have been many accomplishments made over the years to forward this technology for small diameter vessels such as the arteries that feed the heart, and we are excited about the opportunities in the veterinary market to enhance the lives of companion animals with these products. The older our pets get the more they are demonstrating human cardiovascular problems.

Our initial work in developing this biomaterial technology has been funded with competitive research grants from the NIH because of the significance it brings to cardiovascular interventions. The patents we have secured include making small diameter grafts and stents to keep blood vessels open without using anti-platelet therapy, both of which can greatly facilitate cardiovascular interventions for companion animals, as well as other first to market products.”

About Gel-Del Technologies, Inc.
Gel-Del Technologies (www.gel-del.com) is a biomaterial and medical device manufacturing company based in St. Paul, Minnesota. The company successfully completed a pivotal clinical trial using their novel thermoplastic biomaterial as an injected dermal filler for human facial contour applications (clinicaltrials.gov NCT00414544).

Gel-Del’s core competencies include the development and manufacturing of medical devices containing its proprietary biomaterials with or without pharmaceuticals. Using its patented thermoplastic and/or compression manufacturing technologies, purified proteins and carbohydrates are accurately self-assembled and fabricated into cell supporting and tissue compatible biomaterial scaffolds. These “made from scratch” biological scaffolds have the hydrophilic biomimetic structure of the body’s non-cellular tissue allowing in vivo biochemical interaction, cellular integration, neovascularization, tissue repair, tissue absorption and regeneration as a temporary or permanent implant. This biomaterial platform has an interlocking proteinaceous structure with inherit molecular forces to contain added components and/or allow their elution for drug delivery at prescribed durations to any body tissue (e.g., transmucosal, injected or implant depots for minutes to months duration).

These non-soluble biomaterials are produced using a patented and reproducible-scalable process that is FDA-validated for human clinical trial production. The inherent properties of these biomaterials allow thermoplastic, compression molding or liquid coating techniques to manufacture implantable devices of all shapes and sizes, including particles for injection and as drug delivery devices at any pharmaceutical dose.

About PetVivo, Inc:
PetVivo, Inc. is a wholly owned subsidiary of PetVivo Holdings, Inc. (OTCPINK:PETV) based in Minneapolis, Minnesota. PetVivo is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices and other therapeutics for pets.

PetVivo believes that it can leverage the investments in the human biomaterials and medical device industries to commercialize therapeutics to pets in a capital and time efficient way. PetVivo’s strategy is to in-license proprietary products from human medical device companies specifically for use in pets. A key component of this strategy is the accelerated timeline to revenues for veterinary medical devices, which enter the market much earlier than the more stringently regulated pharmaceuticals.

Forward-Looking Statements:
The foregoing material may contain forward-looking statements. We caution that such statements may be subject to uncertainties and that actual results could differ materially from the forward-looking statements. Readers accordingly should not place undue reliance on these forward-looking statements, which do not reflect unknown or unanticipated events or circumstances occurring after the date of these forward-looking statements.

Real Time Web Analytics